Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Shares Outstanding (Diluted Average) (2021 - 2026)

Cogent Biosciences' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $162.2 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 43.15% to $162.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $162.2 million through Mar 2026, up 43.15% year-over-year, with the annual reading at $128.9 million for FY2025, 24.11% up from the prior year.
  • Shares Outstanding (Diluted Average) came in at $162.2 million for Q1 2026, up from $128.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $162.2 million in Q1 2026 to a low of $77968.0 in Q3 2023.
  • The 5-year median for Shares Outstanding (Diluted Average) is $97.0 million (2024), against an average of $89.2 million.
  • Year-over-year, Shares Outstanding (Diluted Average) tumbled 99.86% in 2023 and then skyrocketed 141195.89% in 2024.
  • Cogent Biosciences' Shares Outstanding (Diluted Average) stood at $58.7 million in 2022, then surged by 35.61% to $79.7 million in 2023, then surged by 30.38% to $103.9 million in 2024, then grew by 24.11% to $128.9 million in 2025, then increased by 25.83% to $162.2 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Shares Outstanding (Diluted Average) are $162.2 million (Q1 2026), $128.9 million (Q4 2025), and $137.6 million (Q3 2025).